In the News


Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO™

Unique activity Noted in Drug: Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities announced today that it has presented data on the toxicology, pharmacokinetic and pharmacodynamic profile of its novel anti-neutropenia drug, ANF-RHO.

Prolong Pharmaceuticals Hosts Workshop at the Society for Blood Advancement

Prolong Pharmaceuticals presented at the 2016 Society for Blood Advancement (SABM) meeting in Grand Rapids Michigan. The Workshop entitled Clinical Use of SANGUINATE in Patients for Whom Blood is Not an Option provided an overview of the use of SANGUINATE followed by the presentation of a case report of a patient who received SANGUINATE for life threatening anemia.

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of at the 44th Annual Convention of the Sickle Cell Disease Association of America

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of at the 44th Annual Convention of the Sickle Cell Disease Association of America.

NY/NJ CEO Biotech Conference to Feature Prominent CEOs -- November 11 & 12, Prolong's President, Glenn Kazo, to present.

NY/NJ CEO is an off-the-record networking and educational forum for leading executives in life sciences, offering exclusive access to key decision makers who influence ...

ASCO 2015 publishes Prolong Pharmaceuticals, LLC’s e-Abstract of the Potential use of PEG – HbCO in severe anemia in 5 eIND patients

Abstract: Background: Patients who cannot receive blood transfusions in the presence of severe anemia can sustain significant morbidity and mortality. Religious beliefs and hemolytic reactions are the most common reasons for not transfusing a patient. Pegylated bovine carboxyhemoglobin (PEG-HbCO) has been used in 5 such patients

Prolong Expands Operations (& Potential for Success)

Prolong recently announced the expansion of its South Plainfield, New Jersey, biologics processing facility, adding 24,000 square feet in a move that essentially doubles its original manufacturing capacity to 48,000 square feet...

Prolong Pharmaceuticals Moves Into New Headquarters

Prolong Pharmaceuticals LLC announced the expansion of its South Plainfield, N.J., manufacturing facility. A new long-term lease on the space adjoining its current facility is adding 24,000 square feet to the existing 24,000 square feet. In addition, the company secured 12,000 square feet of new executive and administrative space...

Use of SANGUINATE in encephalopathy from severe sickle cell disease

Patients with sickle cell anemia (SCD) are at increased stroke risk. Periodic blood transfusions decrease tim-averaged mean of the maximum velocities of...

Strategic Approach Needed for International Clinical Trials

Over the past two decades, the decision process for siting overseas clinical trials has become more complex for U.S. pharmaceutical companies. Once a straightforward analysis rooted in time and money, longer-term strategic issues...